Literature DB >> 11156588

Inhibition by glucocorticoids of the mast cell-dependent weal and flare response in human skin in vivo.

Z A Cole1, G F Clough, M K Church.   

Abstract

1. This study examines the relative contributions made by inhibition of mast cell degranulation, reduction of mast cell recruitment and maturation, and lowering the responsiveness of the vasculature to histamine, in the inhibition by glucocorticoids of the weal and flare in human skin. 2. One forearm of healthy human volunteers was treated for 24 h (n=6) or daily for 21 days (n=10) with 0.05% clobetasol propionate. The other arm served as control. Weal and flare responses were elicited by intradermal injection of 20 microl of 0.3 mM codeine. The areas of the responses were measured using scanning laser Doppler imaging. Microdialysis was used to assess histamine release. Mast cell numbers and tissue histamine content were assessed in 4-mm punch biopsies. Histamine (20 microl of 1 microM i.d.) was used to assess the status of the vasculature. 3. No significant effects were seen at 24 h. At 21 days, clobetasol reduced the areas of the codeine-induced weal and flare responses by 59 and 58% respectively (both P=0.006). Mast cell numbers were reduced by 47%, (P=0.014) and total tissue histamine content by 52% (P=0.006). Codeine-induced histamine release was reduced by 44% (P=0.022). The weal, but not the flare, induced by histamine was significantly inhibited (P=0.019). Echography revealed a 15% thinning of the skin by clobetasol. 4. These results demonstrate that reduction of the weal and flare responses to codeine following clobetasol treatment, results primarily from reduced mast cell numbers and tissue histamine content rather than inhibition by corticosteroids of mast cell degranulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11156588      PMCID: PMC1572547          DOI: 10.1038/sj.bjp.0703789

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  Some effects of corticosteroids on the metabolism of histamine and 5-hydroxytryptamine in the rat.

Authors:  J M TELFORD; G B WEST
Journal:  Br J Pharmacol Chemother       Date:  1961-06

2.  Is the histamine skin test inhibited by prednisone?

Authors:  C López-Campos; C B Rincón-Castañeda; P Cano-Ríos; V A Martínez-Ordaz; V M Velasco-Rodríguez
Journal:  Arch Med Res       Date:  1998       Impact factor: 2.235

3.  Tachyphylaxis to histamine-induced wheal suppression by topical 0.05% clobetasol propionate in normal versus croton oil-induced dermatitic skin.

Authors:  S Singh; A Gupta; S S Pandey; G Singh
Journal:  Dermatology       Date:  1996       Impact factor: 5.366

4.  Local injection of recombinant human stem cell factor promotes human skin mast cell survival and neurofibroma cell proliferation in the transplanted neurofibroma in nude mice.

Authors:  T Demitsu; T Kiyosawa; M Kakurai; S Murata; H Yaoita
Journal:  Arch Dermatol Res       Date:  1999-06       Impact factor: 3.017

5.  Role of nitric oxide in the regulation of microvascular perfusion in human skin in vivo.

Authors:  G F Clough
Journal:  J Physiol       Date:  1999-04-15       Impact factor: 5.182

6.  In vivo prevention of corticosteroid-induced skin atrophy by tretinoin in the hairless mouse is accompanied by modulation of collagen, glycosaminoglycans, and fibronectin.

Authors:  E Schwartz; J A Mezick; G J Gendimenico; L H Kligman
Journal:  J Invest Dermatol       Date:  1994-02       Impact factor: 8.551

7.  The effect of dexamethasone on serum protein extravasation and edema development in experimental brain tumors of cat.

Authors:  K A Hossmann; T Hürter; U Oschlies
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

8.  Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells.

Authors:  R P Schleimer; E S Schulman; D W MacGlashan; S P Peters; E C Hayes; G K Adams; L M Lichtenstein; N F Adkinson
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

9.  Early effects of corticosteroids on basophils, leukocyte histamine, and tissue histamine.

Authors:  E H Dunsky; B Zweiman; E Fischler; D A Levy
Journal:  J Allergy Clin Immunol       Date:  1979-06       Impact factor: 10.793

10.  Inhibition of the dermal immediate allergic reaction through prolonged treatment with topical glucocorticosteroids.

Authors:  M Andersson; U Pipkorn
Journal:  J Allergy Clin Immunol       Date:  1987-02       Impact factor: 10.793

View more
  4 in total

1.  Dexamethasone rapidly suppresses IL-33-stimulated mast cell function by blocking transcription factor activity.

Authors:  Anuya Paranjape; Oksana Chernushevich; Amina Abdul Qayum; Andrew J Spence; Marcela T Taruselli; Daniel Abebayehu; Brian O Barnstein; Jamie Josephine Avila McLeod; Bianca Baker; Gurjas S Bajaj; Alena P Chumanevich; Carole A Oskeritzian; John J Ryan
Journal:  J Leukoc Biol       Date:  2016-07-21       Impact factor: 4.962

2.  Glucocorticoids for acute urticaria: study protocol for a double-blind non-inferiority randomised controlled trial.

Authors:  Nicolas Javaud; Angele Soria; Maxime Maignan; Ludovic Martin; Vincent Descamps; Olivier Fain; Laurence Bouillet; Frederic Berard; Karim Tazarourte; Pierre-Marie Roy; Jean-Paul Fontaine; Martine Bagot; Mehdi Khellaf; Helene Goulet; Frederic Lapostolle; Enrique Casalino; Marie-Sylvie Doutre; Cedric Gil-Jardine; Frederic Caux; Olivier Chosidow; Dominique Pateron; Eric Vicaut; Frederic Adnet
Journal:  BMJ Open       Date:  2019-08-21       Impact factor: 2.692

3.  Inhibitory effect of topical adelmidrol on antigen-induced skin wheal and mast cell behavior in a canine model of allergic dermatitis.

Authors:  Santiago Cerrato; Pilar Brazis; Maria Federica Della Valle; Alda Miolo; Anna Puigdemont
Journal:  BMC Vet Res       Date:  2012-11-26       Impact factor: 2.741

4.  Stigmasterol Alleviates Cutaneous Allergic Responses in Rodents.

Authors:  Aaron O Antwi; David D Obiri; Newman Osafo; Leslie B Essel; Arnold D Forkuo; Clement Atobiga
Journal:  Biomed Res Int       Date:  2018-07-24       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.